Based on the Atea Pharmaceuticals Inc stock forecast from 1 analysts, the average analyst target price for Atea Pharmaceuticals Inc is USD 6.00 over the next 12 months. Atea Pharmaceuticals Inc’s average analyst rating is Hold . Stock Target Advisor’s own stock analysis of Atea Pharmaceuticals Inc is Slightly Bearish, which is based on 4 positive signals and 6 negative signals. At the last closing, Atea Pharmaceuticals Inc’s stock price was USD 2.96. Atea Pharmaceuticals Inc’s stock price has changed by +3.50% over the past week, +1.02% over the past month and -20.22% over the last year.
No recent analyst target price found for Atea Pharmaceuticals Inc
No recent average analyst rating found for Atea Pharmaceuticals Inc
Company Overview Atea Pharmaceuticals Inc
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV). It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of ruzasvir. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts. Read Less
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruz...Read More
Frequently Asked Questions About Atea Pharmaceuticals Inc (AVIR) Stock
Based on ratings from 1 analysts Atea Pharmaceuticals Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AVIR's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AVIR is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
AVIR stock's Price/Earning ratio is 9.85.
Our analysis grades AVIR stock's Price / Earning ratio at F. This means that AVIR stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AVIR may be a overvalued for its sector.
The last closing price of AVIR's stock was USD 2.96.
The most recent market capitalization for AVIR is USD 0.25B.
Based on targets from 1 analysts, the average taret price for AVIR is projected at USD 6.00 over the next 12 months.
This means that AVIR's stock price may go up by +102.70% over the next 12 months.
We can't find any ETFs which contains Atea Pharmaceuticals Inc's stock.
As per our most recent records Atea Pharmaceuticals Inc has 56 Employees.
Atea Pharmaceuticals Inc's registered address is 225 Franklin Street, Boston, MA, United States, 02110.
You can get more information about it from Atea Pharmaceuticals Inc's website at https://ateapharma.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Frequently Asked Questions About Atea Pharmaceuticals Inc (AVIR) Stock
Based on ratings from 1 analysts Atea Pharmaceuticals Inc's stock is Hold . Stock Target Advisor's fundamental analysis is Slightly Bearish. The stock has buy, sell and 1 hold ratings.
Unfortunately we do not have enough data on AVIR's stock to indicate if its a good dividend stock.
Based on targets from 1 analysts, the average taret price for AVIR is USD 6.00 over the next 12 months. The maximum analyst target price is USD 6 while the minimum anlayst target price is USD 6.
AVIR stock's Price/Earning ratio is 9.85.
Our analysis grades AVIR stock's Price / Earning ratio at F. This means that AVIR stock's Price/Earning ratio is above 57.00000000000001% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this AVIR may be a overvalued for its sector.
The last closing price of AVIR's stock was USD 2.96.
The most recent market capitalization for AVIR is USD 0.25B.
Based on targets from 1 analysts, the average taret price for AVIR is projected at USD 6.00 over the next 12 months.
This means that AVIR's stock price may go up by +102.70% over the next 12 months.
We can't find any ETFs which contains Atea Pharmaceuticals Inc's stock.
As per our most recent records Atea Pharmaceuticals Inc has 56 Employees.
Atea Pharmaceuticals Inc's registered address is 225 Franklin Street, Boston, MA, United States, 02110.
You can get more information about it from Atea Pharmaceuticals Inc's website at https://ateapharma.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for AVIR !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
